New Light-Activated Platform Advances Glioblastoma Surgery and Postoperative Treatment

Residual microscopic disease and the blood–brain barrier limit the effectiveness of adjuvant therapies, driving a low five‑year survival rate. Surgeons also struggle to distinguish tumor margins intraoperatively without harming eloquent brain regions. To help address this challenge, researchers have developed a light‑activated nanoparticle platform that guides resection and targets remaining cancer cells postoperatively.

Developed by the University of Technology Sydney (UTS) with collaborators at Harvard University and Henan University, the “double‑punch” nanozyme platform integrates intraoperative imaging and postoperative therapy into one material. The design uses an ultrathin, two‑dimensional sheet with single atoms precisely deposited using a semiconductor‑inspired method. Both functions are triggered by the same near‑infrared light to streamline operative workflows.

For guidance during surgery, the material operates as a sensitive imaging agent. A fluorescent dye engineered onto the sheet emits under near‑infrared illumination, allowing visualization of tumor cell clusters reportedly as small as 44 micrometers. A targeting molecule assists transport across the blood–brain barrier and promotes selective accumulation in glioma cells, improving delineation of tumor from normal parenchyma.

After visible tumor is removed, the same material is placed into the resection cavity and re‑illuminated for postoperative phototherapy. Platinum atoms on the sheet convert endogenous hydrogen peroxide into oxygen to counter tumor hypoxia, which otherwise reduces treatment efficacy. Concurrent light exposure generates heat and reactive species intended to destroy residual microscopic disease.

In mouse models of glioblastoma, the approach suppressed postoperative recurrence. Treated animals achieved 100% survival at 60 days, compared with a survival of 42 days for surgery alone, without detectable neurological or motor deficits on follow‑up testing. The work was published in Science Translational Medicine on August 5, 2026.

The investigators note the findings are early‑stage and preclinical. Imaging and therapeutic performance will require confirmation at the scale of the human brain before clinical translation. If validated, the platform could unify fluorescence‑guided surgery and localized adjuvant therapy to reduce recurrence risk.

“During surgery, it functions as a highly sensitive imaging agent. A fluorescent dye engineered onto the sheet glows under a near‑infrared wavelength invisible to the naked eye, allowing surgeons to see individual tumour cell clusters as small as 44 micrometres, a resolution beyond current clinical imaging tools. A targeting molecule attached to the material also helps it cross the blood‑brain barrier and accumulate specifically in glioma cells,” said Dr Bingyang Shi, Chair Professor of nanomedicine from the School of Electrical, Mechanical and Biomedical Engineering at UTS.

“After the visible tumour is removed, the same material is administered into the surgical cavity and reactivated with the same wavelength of light for postoperative phototherapy. The platinum atoms convert the tumour's own hydrogen peroxide into oxygen, counteracting the low‑oxygen environment that normally shields cancer cells from treatment, while the light simultaneously generates heat and reactive molecules that destroy microscopic cancer cells that surgery could not reach,” said Professor Shi.

“The results are very encouraging, but this is still early‑stage research carried out in mouse models, not in people – and that distinction is important. Its imaging and therapeutic performance will also need to be confirmed at the scale of a human brain. If this continues to hold up through that process, the hope is that surgeons could one day see more of the tumour during an operation and treat more of what’s left behind afterwards. It's a meaningful step towards reducing recurrence, which remains one of the biggest challenges for people with glioblastoma,” added  Professor Shi.

Related Links
University of Technology Sydney